Acumen Pharmaceuticals (ABOS) to Release Quarterly Earnings on Tuesday

Acumen Pharmaceuticals (NASDAQ:ABOS) is expected to be announcing its Q1 2025 earnings results before the market opens on Tuesday, May 13th. Analysts expect Acumen Pharmaceuticals to post earnings of ($0.94) per share for the quarter.

Acumen Pharmaceuticals (NASDAQ:ABOS) last posted its earnings results on Thursday, March 27th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.15). On average, analysts expect Acumen Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Acumen Pharmaceuticals Price Performance

Shares of ABOS traded down $0.02 during trading hours on Tuesday, reaching $1.03. The stock had a trading volume of 16,928 shares, compared to its average volume of 290,012. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.43 and a current ratio of 10.43. Acumen Pharmaceuticals has a 12 month low of $0.86 and a 12 month high of $3.92. The stock has a market capitalization of $62.09 million, a PE ratio of -0.74 and a beta of 0.09. The company’s 50-day moving average is $1.12 and its two-hundred day moving average is $1.71.

Analyst Ratings Changes

Several research firms have commented on ABOS. UBS Group dropped their target price on Acumen Pharmaceuticals from $6.00 to $4.00 and set a “buy” rating for the company in a research report on Friday, March 28th. HC Wainwright dropped their price objective on shares of Acumen Pharmaceuticals from $15.00 to $11.00 and set a “buy” rating for the company in a report on Friday, March 28th.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.